• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Bionical acquires Global CRO Emas Pharma

Bionical acquires Global CRO Emas Pharma

November 14, 2016
CenterWatch Staff

Bionical, the integrated outsourced specialist to the pharmaceutical, biotechnology and public health industry, has announced the strategic acquisition of Emas Pharma, a global CRO. Emas, which provides pharmaceutical development and clinical research services to biotech, medical device and specialized pharmaceutical companies worldwide, will join Bionical's existing fast growing clinical services business. Financials were not disclosed.

The acquisition is part of Bionical's strategy to provide high quality clinical, commercial and communications services to pharmaceutical, biotech and public health companies in the global healthcare industry.

The acquisition of Emas and the addition of clinical research, pharmacovigilance, regulatory, medical information and medical affairs capabilities will support Bionical's mission to deliver improved health outcomes for patients. Bionical's clinical division currently provides the supply of comparator products for clinical trials as well as nurse educator teams and public health services and has a wide base of clients internationally. Emas, which has a significant client base of emerging and specialized biopharma companies, brings an extended global footprint, with offices in the U.K., U.S., Canada, Australia and Ireland.

Graham McIntosh, CEO of Bionical, said, "Emas Pharma is a fantastic business with great people and an excellent reputation. Emas's services are highly complementary to Bionical's existing clinical trial services and the acquisition creates opportunities for both businesses to bring enhanced services to their clients. We are very pleased Peter Kennerley, Liz McCann and the Emas team are now a part of Bionical and I look forward to working with them to continue the global growth of Emas."

Dr Peter Kennerley, CEO of Emas Pharma, said, "We are delighted to join the Bionical group, which is a perfect synergy for Emas Pharma.  Being part of a wider family of companies means that we will be offering our clients an even broader range of services to complement our current offerings; from nurse specialists to help track patients lost to follow up, to call centers for Medical Information and from Clinical Trial Supply support to healthcare communications. Liz and I are proud of the excellent reputation for high quality, cost effective support that Emas has built up over the years.  We know that joining Mac and the Bionical team will help us extend that reputation even further."

Emas will continue to operate as a separate business under the existing leadership of Peter Kennerley and Peter will join the Bionical board.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing